SPY
736.53
+0.17%
QQQ
657.50
+0.21%
BTC/USD
75,778.80
+0.04%
DIA
512.52
+0.06%
GLD
373.37
+0.23%
TLT
81.85
−0.09%
Try
Free
US
Sign in
Register
My Account
Benzinga
Premium Services
Services
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
AbbVie Inc
ABBV
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$291.31
3.07
1.07%
Last update: Nov 6, 4:36 PM
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Dividends
Compare
Options
Stock Report
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
AbbVie Financials
AbbVie (ABBV) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
AbbVie Analysts Raise Price Target After Q3 Print, Expect Growth To Reaccelerate
AbbVie shares fell 2% despite Q3 revenue and EPS beats; analysts raised targets, citing immunology strength and long-term growth prospects.
Priya Nigam
These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results
AbbVie beats Q3 estimates, raises 2026 revenue and earnings outlook, while analysts lift price targets to as high as $338.
Avi Kapoor
AbbVie Raises 2026 Outlook, Boosts Dividend
AbbVie hits a new 52-week high after beating Q3 2026 earnings estimates, raising its full-year guidance, and boosting its dividend.
Vandana Singh
PRO
Conference call: AbbVie Raises FY2026 Sales Guidance from $67.600B to $67.800B vs $67.585B Est
AbbVie (NYSE:ABBV) raises FY2026 sales outlook from $67.600 billion to $67.800 billion vs $67.585 billion estimate.
Benzinga Newsdesk
PRO
Conference call: AbbVie Sees Q4 Adj EPS $3.83-$3.87 vs $3.89 Est; Sees Sales $18.400B vs $18.300B Est
AbbVie (NYSE:ABBV) is looking for Q4 Adj EPS of $3.83-$3.87 vs $3.89 analyst estimate. sees sales of $18.400 billion vs $18.300 billion analyst estimate.
Benzinga Newsdesk
PRO
AbbVie Raises FY2026 Adj EPS Guidance from $13.76-$13.96 to $13.95-$13.99 vs $13.93 Est
AbbVie (NYSE:ABBV) raises FY2026 Adj EPS guidance from $13.76-$13.96 to $13.95-$13.99 vs $13.93 analyst estimate..
Benzinga Newsdesk
